

Neuromuscular Blocker (NMB) Gaps and Solutions

10/01/2024



LIST OF REGISTERED NMB

Generic Name and Strength	Manufacturer Name	Product Name
Atracurium Besilate : 10 mg/ml Solution For Injection	The Wellcome Foundation Limited, UNITED KINGDOM	TRACRIUM
Atracurium Besilate : 10 mg/ml Solution For Injection	Hameln Pharmaceuticals GmbH, GERMANY	ATRACURIUM-HAMELN
Atracurium Besilate : 10 mg/ml Solution For Injection	Glaxo Wellcome S.p.A., ITALY	TRACRIUM
Atracurium Besilate : 10 mg/ml Solution For Injection	Abbott Laboratories, U.S.A	ATRACURIUM BESYLATE
Cisatracurium Besilate : 2 mg/ml Solution For Injection	A S Kalceks, Latvia	Cisatracurium Kalceks
Cisatracurium Besilate : 2 mg/ml Solution For Injection	Al Hikma Pharmaceuticals, JORDAN	SISACURE
Cisatracurium Besilate : 2 mg/ml Solution For Injection	GlaxoSmithKline S.p.A., ITALY	NIMBEX
Cisatracurium Besilate : 5 mg/ml Solution For Injection	Glaxo Wellcome S.p.A., ITALY	NIMBEX FORTE
Cisatracurium Besilate : 2 mg/ml Solution For Injection	Fresenius Kabi Deutschland GmbH, GERMANY	CISATRACURIUM KABI



LIST OF REGISTERED NMB

Generic Name and Strength	Manufacturer Name	Product Name
Pancuronium Bromide : 2 mg/ml Solution For Injection	N.V. Organon, NETHERLANDS	PAVULON
Pancuronium Bromide : 2 mg/ml Solution For Injection	David Bull Laboratories, AUSTRALIA	PANCURONIUM
Rocuronium Bromide : 10 mg/ml Solution For Injection	Labatec-Pharma S.A., SWITZERLAND	ROCALM
Rocuronium Bromide : 10 mg/ml Solution For Injection	Al Hikma Pharmaceuticals, JORDAN	ROCURON
Rocuronium Bromide : 10 mg/ml Solution For Injection	N.V. Organon, NETHERLANDS	ESMERON
Rocuronium Bromide : 10 mg/ml Solution For Injection	Labatec-Pharma S.A., SWITZERLAND	ROCRON
Vecuronium bromide : 10 mg Powder For Solution For Injection	N.V. Organon, NETHERLANDS	NORCURON
Mivacurium Chloride : 2 mg/ml Solution For Injection	The Wellcome Foundation Limited, UNITED KINGDOM	MIVACRON
Suxamethonium Chloride : 10 mg Solution For Injection	Laboratoire Aguettant, FRANCE	SUXAMETHONIUM AGUETTANT
Suxamethonium Chloride : 50 mg/ml Solution For Injection	The Wellcome Foundation Limited, UNITED KINGDOM	ANECTINE (MIDARINE)





Neuromuscular Blocker Safe

1.	kind	lly choose the NMB agent that is available in your facilit
		Pancuronium
		Rocuronium
		Vecuronium
		Atracurium
		Mivacurium
		Cisatracurium
		Suxamethonium
		Other
2.		ere any warning on the outer & inner pack of the NMB "Cau ent Must Be Ventilated, patient shall be in ventilation etc."? *
	0	Yes
	0	No
3.	Facil	lity name *
	Ent	ter your answer

 Short survey has been shared to all PV focal points at hospitals in Emirate of Abu Dhabi, asking for the NMB available and if any warning on the outer and inner pack of NMB "Causes Respiratory Arrest – Patient must be ventilated, patient shall be in ventilation etc."



2. Is there any warning on the outer & inner pack of the NMB "Causes Respiratory Arrest — Patient Must Be Ventilated, patient shall be in ventilation etc."?

More Details






CISATRACURIUM (NORMON®)

CONCERN


- · No "Paralyzing Agent" on the cap as recommended by FDA
- No indication anywhere on package that it is a paralyzing agent
- · Labeling in Spanish











SUXAMETHONIUM PRE-FILLED SYRINGE





CONCERN

No indication anywhere on package by the manufacturer that it is a paralyzing agent






ROCURONIUM (ESMERON®)

CONCERN

No "Paralyzing Agent" on the cap as recommended by FDA









SUXAMETHONIUM AGUETTANT 10 mg/ml Solution for injection in pre-filled syringe

Suxamethonium chloride anhydrous - W Store in a refrigerator (2°C - 8°C). Do not treeze. After opening, the medicinal product must be used immediately.

100 mg 10 ml



03 05 2024

04-05 2022 10:40

POTENTIAL TO CAUSE UNINTENDED PARALYSIS, RESPIRATORY ARREST, SEVERE PERMANENT HARM, OR DEATH - PATIENT MUST BE VENTILATED

50 mg = 5 ml

Rocuronium Bromide

10 vials each vial contains 5ml

For Intravenous use

0 mg

POTENTIAL TO CAUSE UNINTENDED PARALYSIS, RESPIRATORY ARREST, SEVERE PERMANENT HARM, OR DEATH - PATIENT MUST BE VENTILATED

MSD MSD

POTENTIAL TO CAUSE UNINTENDED PARALYSIS, RESPIRATORY ARREST, SEVERE PERMANENT HARM, OR DEATH - PATIENT MUST BE VENTILATED

intravenous Injection Cisatracurium besylate

20 mg cisatracurium (bis-cation) in 10 ml 5 ampoules


For intravenous injection





DoH pharmacovigilance team reach out all focal points at hospitals in Emirate of Abu Dhabi asking for:

- Reporting medication errors and safety issues regarding the use of neuromuscular blockers (NMB).
- Current practice used and the changes/recommendations done regarding the safe use of neuromuscular blockers (NMB)



Current Practice



Storage 01

02 Prescribing Dispensing/ Preparation 03

Administration 04

05 Monitoring Education 06

Storage

- High alert medication
- The storage compartments labelled as "High Alert" AND "Paralyzing agent – causes respiratory arrest" with a printed label specifying drug description.
- Auxiliary labels "Paralyzing agent causes respiratory arrest".
- Pharmacy keeps a mobile intubation kit "containing NMBAs" which is delivered when intubation is performed outside critical areas.




Prescribing

- Appears in red font at time of prescribing, and flagged as "High Alert".
- Prescribing NMBAs triggers a patientspecific & real-time clinical decision support alerts.









Dispensing/ Preparation

- Each syringe prepared by pharmacy will be flagged with "Paralytic Agent Use with Caution"
- Restricted to ICU, CCU, NICU, Anaesthesia, ED, OR, PACU only.
- Auxiliary labels
- NMBAs has a designated caution label attached to each dose and in the storage bin.
- NMBs are mainly used in Operation Theatre. In case it is outside the OT, orders for NMBs will be dispensed only on areas where ventilator is available.

An auxiliary label with the following "WARNING: PARALYZING AGENT: PATIENT MUST BE VENTILATED" is applied on the following:

Ampoules/Vials

IV Bags (Applied by Pharmacy)

IV Lines (Applied by Nursing)



















Recommendation

- Clear and accurate labeling with double revising and rechecking the labeling with warning and high alert label.
- There should be a regular training specifically for NMBs to increase the awareness for this specific group of medicine, not only for OT staff, but for all medical professionals who might deal with NMBs.
- Use neuromuscular blockers" or "paralyzing agents while prescribing.
- Orient the staff about the risk of serious errors with these <u>high-alert drugs</u>.
- Generate training program and competency verification process for practitioners involved in preparing, dispensing, and administering neuromuscular blockers.



